Cell News and Research

RSS

Efficient, economical molecule could speed evaluation of some anti-cancer treatments

Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.

14 Sep 2011

Intrauterine devices may protect against cervical cancer

Intrauterine devices (IUDs) may protect against cervical cancer. This is the conclusion of the broadest epidemiological study to date in which has participated the research group in Viruses and Cancer of IDIBELL, published at The Lancet Oncology.

14 Sep 2011

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Seattle Genetics, Inc. and Oxford BioTherapeutics today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer.

14 Sep 2011

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536.

14 Sep 2011

Henry Ford study identifies 23 microRNAs for laryngeal cancer

A Henry Ford Hospital study has identified 23 microRNAs for laryngeal cancer, a discovery that could yield new insight into what causes certain cells to grow and become cancerous tumors in the voice box.

14 Sep 2011

Combining cell biology and molecular genetics for single-cell research

Fluidigm Corporation has announced a collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), to co-host a public seminar series on the isolation and analysis of single cells. Entitled 'A Powerful Technique for Single-Cell Analysis', the public seminar series will showcase cell isolation using the BD FACSAria™ III Cell Sorter and analysis using the Fluidigm BioMark™ HD System.

13 Sep 2011

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Bayer HealthCare announced today that the company will present data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

13 Sep 2011

New drug combination may treat two aggressive cancers

Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011.

13 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL.

13 Sep 2011

UC Berkeley scientists offer treatment hope for patients with tinnitus

Neuroscientists at the University of California, Berkeley, are offering hope to the 10 percent of the population who suffer from tinnitus - a constant, often high-pitched ringing or buzzing in the ears that can be annoying and even maddening, and has no cure.

13 Sep 2011

Researchers identify new type of potential anticancer drug

Researchers at Emory University School of Medicine have identified a new type of potential anticancer drug. The compound, named FOBISIN, targets 14-3-3 proteins, important for the runaway growth of cancer cells.

13 Sep 2011

Cardiotrophin 1 has marked effect on fat and glucose metabolism

Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism.

13 Sep 2011

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

13 Sep 2011

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington’s patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington’s often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.

12 Sep 2011

University of Adelaide research focuses on techniques to treat swallowing disorders

A simple function that most of us take for granted - swallowing - is the focus of University of Adelaide research which could help thousands of stroke sufferers around the world.

12 Sep 2011

Reducing malaria incidence could also drastically reduce deaths from bacterial infections, study says

"Reducing the incidence of malaria could also drastically reduce the number of deaths from bacterial infections among children in Africa, a study" published last week in the Lancet found, according to SciDev.Net.

12 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Chromatin, Dow AgroSciences achieve first milestone in research collaboration

Chromatin Inc. announced today that they have reached the first milestone in their research collaboration with Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company. This collaboration is focused on developing a novel combination of Chromatin's Mini-Chromosomes with Dow AgroSciences' EXZACT Precision Technology.

12 Sep 2011

Cell News and Research

Efficient, economical molecule could speed evaluation of some anti-cancer treatments

Intrauterine devices may protect against cervical cancer

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Henry Ford study identifies 23 microRNAs for laryngeal cancer

Combining cell biology and molecular genetics for single-cell research

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

New drug combination may treat two aggressive cancers

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

UC Berkeley scientists offer treatment hope for patients with tinnitus

Researchers identify new type of potential anticancer drug

Cardiotrophin 1 has marked effect on fat and glucose metabolism

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

University of Adelaide research focuses on techniques to treat swallowing disorders

Reducing malaria incidence could also drastically reduce deaths from bacterial infections, study says

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Chromatin, Dow AgroSciences achieve first milestone in research collaboration

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News